Role of Uterotonics in Reducing Intraoperative Blood Loss in Patients With PASD Undergoing Cesarean Hysterectomy

Role of Uterotonics in Reducing Intraoperative Blood Loss in Patients With Placenta Accrete Spectrum Disorders Undergoing Cesarean Hysterectomy

Objectives: To evaluate the effect of oxytocin in reducing intraoperative blood loss in patients with PAS disorders planned for cesarean hysterectomy.

Inclusion Criteria:

• Pregnancy of singleton living fetus
• Previous one or more cesarean sections
• Gestational age: > 32 weeks
• The following ultrasound markers such as "loss of clear retroplacental translucency", "myometrial thinning", "abnormal lacunae", "irregular bladder wall", "utero-vesicalhypervascularity".
• Preoperative hemoglobin more than 10 gm/dl
• Cases with PAS that will undergoing CS Hysterectomy

Exclusion Criteria:

• Maternal medical disorders e.g.: coagulation defects, cardiac diseases etc.….
• Any known or reported hypersensitivity to the used medication.
• All cases with spontaneous placental separation at laparotomy.
• All patients undergoing conservative management of PAS.
• All cases which necessitate emergency termination.